Greg Hapgood

966 total citations
28 papers, 390 citations indexed

About

Greg Hapgood is a scholar working on Pathology and Forensic Medicine, Oncology and Dermatology. According to data from OpenAlex, Greg Hapgood has authored 28 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 10 papers in Oncology and 5 papers in Dermatology. Recurrent topics in Greg Hapgood's work include Lymphoma Diagnosis and Treatment (20 papers), Cutaneous lymphoproliferative disorders research (5 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Greg Hapgood is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), Cutaneous lymphoproliferative disorders research (5 papers) and CNS Lymphoma Diagnosis and Treatment (4 papers). Greg Hapgood collaborates with scholars based in Australia, Canada and United Kingdom. Greg Hapgood's co-authors include Kerry J. Savage, Sanjeev Chunilal, Erica Malan, Diego Villa, Randy D. Gascoyne, Tom Pickles, Alina S. Gerrie, David W. Scott, Christina Parsons and Laurie H. Sehn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Bioinformatics.

In The Last Decade

Greg Hapgood

22 papers receiving 383 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Greg Hapgood Australia 9 226 123 73 69 66 28 390
Miguel Arturo Pavlovsky Argentina 8 362 1.6× 107 0.9× 46 0.6× 56 0.8× 27 0.4× 35 577
Erjiang Tang China 10 148 0.7× 177 1.4× 38 0.5× 12 0.2× 55 0.8× 22 368
Adam Ackerman United States 5 340 1.5× 226 1.8× 39 0.5× 69 1.0× 22 0.3× 8 491
Jordan A. Herst Canada 7 263 1.2× 201 1.6× 14 0.2× 51 0.7× 29 0.4× 12 401
Bosko Andjelic Serbia 12 244 1.1× 140 1.1× 6 0.1× 34 0.5× 28 0.4× 37 359
Ahmet Demirkazık Türkiye 12 68 0.3× 193 1.6× 10 0.1× 43 0.6× 86 1.3× 29 426
Roberto Freilone Italy 13 420 1.9× 321 2.6× 22 0.3× 15 0.2× 10 0.2× 46 591
Ülkü Yalçıntaş Arslan Türkiye 11 106 0.5× 223 1.8× 76 1.0× 20 0.3× 86 1.3× 52 470
Alfredo Rivas‐Delgado Spain 12 264 1.2× 184 1.5× 18 0.2× 39 0.6× 73 1.1× 27 464
Sudha Parasuraman United States 8 78 0.3× 102 0.8× 5 0.1× 53 0.8× 53 0.8× 15 304

Countries citing papers authored by Greg Hapgood

Since Specialization
Citations

This map shows the geographic impact of Greg Hapgood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Hapgood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Hapgood more than expected).

Fields of papers citing papers by Greg Hapgood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Hapgood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Hapgood. The network helps show where Greg Hapgood may publish in the future.

Co-authorship network of co-authors of Greg Hapgood

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Hapgood. A scholar is included among the top collaborators of Greg Hapgood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Hapgood. Greg Hapgood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Erku, Daniel, Joshua W.D. Tobin, John F. Seymour, et al.. (2025). An Economic Evaluation of the TROG 99.03 Trial: Systemic Therapy After Radiotherapy in Early‐Stage Follicular Lymphoma. eJHaem. 6(1). e70002–e70002.
2.
Wellard, Cameron, Allison Barraclough, Belinda A. Campbell, et al.. (2025). Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review. Blood Advances. 9(9). 2275–2284.
3.
Tobin, Joshua W.D., Greg Hapgood, Anna Johnston, et al.. (2024). Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 54(8). 1384–1395. 2 indexed citations
4.
Hapgood, Greg, Kate Hill, Satomi Okano, et al.. (2024). Catheter-related thrombosis in adults with cancer: a secondary analysis of a prospective randomized controlled trial. Journal of Thrombosis and Haemostasis. 23(2). 627–634. 1 indexed citations
5.
Hapgood, Greg, Monica Civallero, Julie M. Vose, et al.. (2023). The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Blood Advances. 7(17). 5047–5054. 1 indexed citations
6.
7.
Hapgood, Greg, Maya Latimer, Sze Ting Lee, et al.. (2021). Diagnosis, management and follow up of peripheral T‐cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 52(10). 1806–1817.
8.
Tobin, Joshua W.D., et al.. (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia & lymphoma. 62(14). 3484–3492. 2 indexed citations
9.
10.
11.
Lo, Andrea, Joseph M. Connors, Alina S. Gerrie, et al.. (2020). Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma. Blood. 136(Supplement 1). 18–19.
12.
Tobin, Joshua W.D., et al.. (2020). A Cost-Effectiveness Analysis of Front-Line Treatment Strategies in Early Stage Follicular Lymphoma. Blood. 136(Supplement 1). 54–55. 1 indexed citations
13.
Dunn, Nathan, et al.. (2019). Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status. Leukemia & lymphoma. 61(3). 721–727. 7 indexed citations
14.
Hapgood, Greg, et al.. (2018). Relative survival of patients with lymphoma in Queensland according to histological subtype. The Medical Journal of Australia. 209(4). 166–172. 4 indexed citations
15.
Blombery, Piers, Ella R. Thompson, Georgina L. Ryland, et al.. (2018). Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. Oncotarget. 9(90). 36126–36136. 57 indexed citations
16.
Hapgood, Greg, Yvonne Zheng, Laurie H. Sehn, et al.. (2016). Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. Journal of Clinical Oncology. 34(21). 2493–2500. 40 indexed citations
17.
18.
19.
Hapgood, Greg & Sukanya Roy. (2013). A mysterious case of Dr Cabot. British Journal of Haematology. 162(6). 719–719.
20.
Hapgood, Greg, et al.. (2012). Leukaemia cutis in chronic lymphocytic leukaemia following varicella zoster virus reactivation. Internal Medicine Journal. 42(12). 1355–1358. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miguel Arturo Pavlovsky Breakdown of academic impact, for papers by Erjiang Tang Breakdown of academic impact, for papers by Adam Ackerman Breakdown of academic impact, for papers by Jordan A. Herst Breakdown of academic impact, for papers by Bosko Andjelic Breakdown of academic impact, for papers by Ahmet Demirkazık Breakdown of academic impact, for papers by Roberto Freilone Breakdown of academic impact, for papers by Ülkü Yalçıntaş Arslan Breakdown of academic impact, for papers by Alfredo Rivas‐Delgado Breakdown of academic impact, for papers by Sudha Parasuraman
Rankless by CCL
2026